D
Didier Cussac
Researcher at French Institute of Health and Medical Research
Publications - 101
Citations - 5172
Didier Cussac is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 39, co-authored 101 publications receiving 4893 citations. Previous affiliations of Didier Cussac include Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Millan Mark,Alain Gobert,Françoise Lejeune,Anne Dekeyne,Adrian Newman-Tancredi,Valérie Pasteau,Jean-Michel Rivet,Didier Cussac +7 more
TL;DR: In contrast to melatonin, agomelatine behaves as an antagonist at 5- HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.
Journal ArticleDOI
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
Millan Mark,Lisa Maiofiss,Didier Cussac,Valérie Audinot,Jean-A. Boutin,Adrian Newman-Tancredi +5 more
TL;DR: An innovative multivariate analysis revealed marked heterogeneity in binding profiles of antiparkinson agents at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease.
Journal ArticleDOI
Ras, Rap, and Rac Small GTP-binding Proteins Are Targets for Clostridium sordellii Lethal Toxin Glucosylation
Michel R. Popoff,Esteban Chaves-Olarte,Emmanuel Lemichez,Emmanuel Lemichez,Christoph von Eichel-Streiber,Monica Thelestam,Pierre Chardin,Didier Cussac,Bruno Antonny,Philippe Chavrier,Gilles Flatau,M Giry,Jean de Gunzburg,Patrice Boquet,Patrice Boquet +14 more
TL;DR: LT is a glucosyltransferase that uses UDP-Glc as a cofactor to covalently modify 21-kDa proteins both in vitro and in vivo, and is thus a powerful tool to inhibit Ras function in vivo.
Journal ArticleDOI
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan Mark,Adrian Newman-Tancredi,Valérie Audinot,Didier Cussac,Françoise Lejeune,Jean-Paul Nicolas,Francis Cogé,Jean-Pierre Galizzi,Jean A. Boutin,Jean-Michel Rivet,Anne Dekeyne,Alain Gobert +11 more
TL;DR: The α2‐AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine, whereas fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover and enhances striatal dopamine turnover and suppresses striatal turnover of 5‐HT.
Journal ArticleDOI
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes
Adrian Newman-Tancredi,Didier Cussac,Yann Quentric,Manuelle Touzard,Laurence Verrièle,Nathalie Carpentier,Millan Mark +6 more
TL;DR: Antiparkinson agents display markedly different patterns of agonist and antagonist properties at multiple 5-HT receptor subtypes, although all show modest (agonist) activity at5-HT1A sites, and their contrasting actions at 5-ht2A and 5- HT2C sites may be of particular significance to their functional profiles in vivo.